Detection of coronary stenosis with myocardial contrast echocardiography using regadenoson, a selective adenosine A 2A receptor agonist

Dai-Trang (Elizabeth) Le, Thanjavur Bragadeesh, Yan Zhao, Yue Gang Wang, Daogang Zha, Sanjiv Kaul

    Research output: Contribution to journalArticle

    5 Citations (Scopus)

    Abstract

    Aims: Regadenoson is comparable to adenosine in pharmacologic radionuclide stress tests but has not been studied with stress myocardial contrast echocardiography. This study assessed the haemodynamic profile and ability of regadenoson, a novel selective A 2A receptor agonist, to detect coronary artery stenosis during myocardial contrast echocardiography. Methods and results: Myocardial contrast echocardiography was performed to measure myocardial blood volume, myocardial blood flow velocity, and total regional myocardial blood flow before and after administration of regadenoson (5 μg kg -1, 10 s bolus) in 10 open-chest dogs with mild-to-moderate coronary stenosis that was not flow limiting at rest. Regadenoson decreased blood pressure but did not change heart rate. It increased coronary blood flow significantly (P <0.05) for 30 min, which was attenuated in proportion to coronary stenosis severity. Whereas myocardial blood volume maximally increased by 0.5-0.75-fold in the control region, it did not change in the region supplied by the nonflow limiting stenosis. Perfusion defects were visually and quantitatively detectable for as long as 10 min after administration of regadenoson. No arrhythmias were noted with regadenoson either prior to or during myocardial contrast echocardiography. Conclusion: Regadenoson can be used as a vasodilator stress agent with myocardial contrast echocardiography to detect the presence of physiologically significant coronary stenosis. The optimum time for image acquisition was 3-10 min after drug administration. Published on behalf of the European Society of Cardiology. All rights reserved.

    Original languageEnglish (US)
    Pages (from-to)298-308
    Number of pages11
    JournalEuropean Heart Journal Cardiovascular Imaging
    Volume13
    Issue number4
    DOIs
    StatePublished - Apr 2012

    Fingerprint

    Adenosine A2A Receptors
    Coronary Stenosis
    Echocardiography
    Blood Volume
    Blood Flow Velocity
    Regional Blood Flow
    regadenoson
    Vasodilator Agents
    Exercise Test
    Radioisotopes
    Adenosine
    Cardiac Arrhythmias
    Pathologic Constriction
    Thorax
    Perfusion
    Heart Rate
    Hemodynamics
    Dogs
    Blood Pressure

    Keywords

    • Myocardial contrast echocardiography
    • Regadenoson
    • Stress testing

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine
    • Radiology Nuclear Medicine and imaging

    Cite this

    Detection of coronary stenosis with myocardial contrast echocardiography using regadenoson, a selective adenosine A 2A receptor agonist. / Le, Dai-Trang (Elizabeth); Bragadeesh, Thanjavur; Zhao, Yan; Wang, Yue Gang; Zha, Daogang; Kaul, Sanjiv.

    In: European Heart Journal Cardiovascular Imaging, Vol. 13, No. 4, 04.2012, p. 298-308.

    Research output: Contribution to journalArticle

    @article{9aff484d4dd34197974b3911e176b96c,
    title = "Detection of coronary stenosis with myocardial contrast echocardiography using regadenoson, a selective adenosine A 2A receptor agonist",
    abstract = "Aims: Regadenoson is comparable to adenosine in pharmacologic radionuclide stress tests but has not been studied with stress myocardial contrast echocardiography. This study assessed the haemodynamic profile and ability of regadenoson, a novel selective A 2A receptor agonist, to detect coronary artery stenosis during myocardial contrast echocardiography. Methods and results: Myocardial contrast echocardiography was performed to measure myocardial blood volume, myocardial blood flow velocity, and total regional myocardial blood flow before and after administration of regadenoson (5 μg kg -1, 10 s bolus) in 10 open-chest dogs with mild-to-moderate coronary stenosis that was not flow limiting at rest. Regadenoson decreased blood pressure but did not change heart rate. It increased coronary blood flow significantly (P <0.05) for 30 min, which was attenuated in proportion to coronary stenosis severity. Whereas myocardial blood volume maximally increased by 0.5-0.75-fold in the control region, it did not change in the region supplied by the nonflow limiting stenosis. Perfusion defects were visually and quantitatively detectable for as long as 10 min after administration of regadenoson. No arrhythmias were noted with regadenoson either prior to or during myocardial contrast echocardiography. Conclusion: Regadenoson can be used as a vasodilator stress agent with myocardial contrast echocardiography to detect the presence of physiologically significant coronary stenosis. The optimum time for image acquisition was 3-10 min after drug administration. Published on behalf of the European Society of Cardiology. All rights reserved.",
    keywords = "Myocardial contrast echocardiography, Regadenoson, Stress testing",
    author = "Le, {Dai-Trang (Elizabeth)} and Thanjavur Bragadeesh and Yan Zhao and Wang, {Yue Gang} and Daogang Zha and Sanjiv Kaul",
    year = "2012",
    month = "4",
    doi = "10.1093/ejechocard/jer232",
    language = "English (US)",
    volume = "13",
    pages = "298--308",
    journal = "European Heart Journal Cardiovascular Imaging",
    issn = "2047-2404",
    publisher = "Oxford University Press",
    number = "4",

    }

    TY - JOUR

    T1 - Detection of coronary stenosis with myocardial contrast echocardiography using regadenoson, a selective adenosine A 2A receptor agonist

    AU - Le, Dai-Trang (Elizabeth)

    AU - Bragadeesh, Thanjavur

    AU - Zhao, Yan

    AU - Wang, Yue Gang

    AU - Zha, Daogang

    AU - Kaul, Sanjiv

    PY - 2012/4

    Y1 - 2012/4

    N2 - Aims: Regadenoson is comparable to adenosine in pharmacologic radionuclide stress tests but has not been studied with stress myocardial contrast echocardiography. This study assessed the haemodynamic profile and ability of regadenoson, a novel selective A 2A receptor agonist, to detect coronary artery stenosis during myocardial contrast echocardiography. Methods and results: Myocardial contrast echocardiography was performed to measure myocardial blood volume, myocardial blood flow velocity, and total regional myocardial blood flow before and after administration of regadenoson (5 μg kg -1, 10 s bolus) in 10 open-chest dogs with mild-to-moderate coronary stenosis that was not flow limiting at rest. Regadenoson decreased blood pressure but did not change heart rate. It increased coronary blood flow significantly (P <0.05) for 30 min, which was attenuated in proportion to coronary stenosis severity. Whereas myocardial blood volume maximally increased by 0.5-0.75-fold in the control region, it did not change in the region supplied by the nonflow limiting stenosis. Perfusion defects were visually and quantitatively detectable for as long as 10 min after administration of regadenoson. No arrhythmias were noted with regadenoson either prior to or during myocardial contrast echocardiography. Conclusion: Regadenoson can be used as a vasodilator stress agent with myocardial contrast echocardiography to detect the presence of physiologically significant coronary stenosis. The optimum time for image acquisition was 3-10 min after drug administration. Published on behalf of the European Society of Cardiology. All rights reserved.

    AB - Aims: Regadenoson is comparable to adenosine in pharmacologic radionuclide stress tests but has not been studied with stress myocardial contrast echocardiography. This study assessed the haemodynamic profile and ability of regadenoson, a novel selective A 2A receptor agonist, to detect coronary artery stenosis during myocardial contrast echocardiography. Methods and results: Myocardial contrast echocardiography was performed to measure myocardial blood volume, myocardial blood flow velocity, and total regional myocardial blood flow before and after administration of regadenoson (5 μg kg -1, 10 s bolus) in 10 open-chest dogs with mild-to-moderate coronary stenosis that was not flow limiting at rest. Regadenoson decreased blood pressure but did not change heart rate. It increased coronary blood flow significantly (P <0.05) for 30 min, which was attenuated in proportion to coronary stenosis severity. Whereas myocardial blood volume maximally increased by 0.5-0.75-fold in the control region, it did not change in the region supplied by the nonflow limiting stenosis. Perfusion defects were visually and quantitatively detectable for as long as 10 min after administration of regadenoson. No arrhythmias were noted with regadenoson either prior to or during myocardial contrast echocardiography. Conclusion: Regadenoson can be used as a vasodilator stress agent with myocardial contrast echocardiography to detect the presence of physiologically significant coronary stenosis. The optimum time for image acquisition was 3-10 min after drug administration. Published on behalf of the European Society of Cardiology. All rights reserved.

    KW - Myocardial contrast echocardiography

    KW - Regadenoson

    KW - Stress testing

    UR - http://www.scopus.com/inward/record.url?scp=84863853279&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84863853279&partnerID=8YFLogxK

    U2 - 10.1093/ejechocard/jer232

    DO - 10.1093/ejechocard/jer232

    M3 - Article

    C2 - 22067143

    AN - SCOPUS:84863853279

    VL - 13

    SP - 298

    EP - 308

    JO - European Heart Journal Cardiovascular Imaging

    JF - European Heart Journal Cardiovascular Imaging

    SN - 2047-2404

    IS - 4

    ER -